GMP for ATMPs - A Detailed View at the European Guidelines

Streaming of Recorded Presentations from 14-16 June 2021
Live Expert Q&A and Panel Discussion on 17 June 2021

Speaker and Panelist
Dr Rainer Gnibl
Government of Upper Bavaria, GMP Inspector

Further Panelists
Dr Sabine Hauck
Leukocare, QP and Chair of ECAs ATMP Interest Group

Dr Andrea Hauser
University Regensburg, Vice Chair of ECAs ATMP Interest Group

Dr Rüdiger Alt
Manager Quality Assurance / Qualified Person ATMP, Novartis

Dr Thomas Meindl
Labor LS

Stefan Gärtner
Labor LS

Highlights
- 11 Hours Presentation Time
- 17 Sections / topics of the Guides
- Live Answering of your Questions
- With 6 Experts from Authority, Academia, Industry and Laboratory

- Watch the lectures over 3 days when it suits you.
- Followed by a Live Q&A with an Expert Panel
Programme

Background
Relating to the increasing importance of advanced therapy medicinal products (ATMPs) the European Commission and the EMA published a joint document in 2007 with a proposal for a community regulatory framework on ATMPs. With the additional comments of DG enterprise and the industry they issued an implementation plan for the ATMP regulation (Regulation (EC) No 1394/2007) with a date for application on 30 December 2008. In this time, the most ATMPs were in a phase of development and questions about scientific advice, registration and following marketing authorisation were more of interest than GMP issues. But with the increasing number of ATMPs and their development into phases with more GMP relevance, a more detailed guidance on Good Manufacturing Practice for Advanced Therapy Medicinal Products pursuant to Article 5 of Regulation 1394/2007 became essential. Therefore, a first consultation on the development of such a GMP for ATMP guideline was started in July 2015.

Then, on 22 November, the European Commission adopted the “New Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products” which came in operation at 22 May 2018.

The new guideline includes requirements for ATMPs with a marketing authorisation as well as for advanced therapy medicinal products that are being tested or used as reference in a clinical trial (i.e. advanced therapy investigational medicinal products). The document should be the main document for the definition of the GMP requirements for ATMPs, so in the scope it states: “These Guidelines do not apply to medicinal products other than ATMPs. In turn, the detailed guidelines referred to in the second paragraph of Article 47 of Directive 2001/83/EC and Article 63(1) of Regulation (EU) No 536/2014 do not apply to ATMPs, unless specific reference thereto is made in these.”

A look at the over 80 pages and the table of content shows that the status as a stand alone guideline has made it necessary to include all important fields with relation to ATMPs which are normally covered for other medicinal products in the existing GMP guideline and its Annexes.

Target Audience
This seminar is aimed at all persons who are involved in
- development
- marketing authorisation
- manufacturing
- quality assurance
- quality control
- or inspection/auditing of ATMPs.

Speaker and Panel Discussion Participants

Speaker and Panelist:

Dr Rainer Gnibl
Government of Upper Bavaria, GMP Inspector

Further Panelists:

Dr Sabine Hauck
Leukocare, QP and Chair of ECAs ATMP Interest Group

Dr Andrea Hauser
University Regensburg, Vice Chair of ECAs ATMP Interest Group

Dr Rüdiger Alt
Manager Quality Assurance / Qualified Person ATMP, Novartis

Dr Thomas Meindl
Labor LS

Stefan Gärtner
Labor LS
Objectives/Programme

This recorded course and accompanying live panel discussion with regulatory agency speakers and experts from university, small and medium industry, and laboratory will feature 17 lectures that provide both a comprehensive overview of the guidance content.

Your questions will be answered by the experts during the live discussion on 17 June 2021.

The Lectures and approx. time:

<table>
<thead>
<tr>
<th>Topic</th>
<th>Length in Minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 EU-GMP for Advanced Therapy Medicinal Products (ATMPs) - an Overview</td>
<td>20</td>
</tr>
<tr>
<td>2 Pharmaceutical Quality System</td>
<td>25</td>
</tr>
<tr>
<td>3 Quality Risk Management</td>
<td>30</td>
</tr>
<tr>
<td>4 Personnel</td>
<td>35</td>
</tr>
<tr>
<td>5 Premises &amp; Zone Concept</td>
<td>60</td>
</tr>
<tr>
<td>6 Equipment</td>
<td>12</td>
</tr>
<tr>
<td>7 Qualification</td>
<td>45</td>
</tr>
<tr>
<td>8 Environmental Monitoring</td>
<td>40</td>
</tr>
<tr>
<td>9 Materials</td>
<td>59</td>
</tr>
<tr>
<td>10 Production</td>
<td>85</td>
</tr>
<tr>
<td>11 Validation</td>
<td>60</td>
</tr>
<tr>
<td>12 Documentation</td>
<td>45</td>
</tr>
<tr>
<td>13 Quality Control</td>
<td>35</td>
</tr>
<tr>
<td>14 QP Certification &amp; Batch Release</td>
<td>75</td>
</tr>
<tr>
<td>15 Outsourced Activities</td>
<td>20</td>
</tr>
<tr>
<td>16 Quality Defects &amp; Product Recalls</td>
<td>20</td>
</tr>
<tr>
<td>17 Specific Products &amp; Processes</td>
<td>20</td>
</tr>
</tbody>
</table>

How it works

As a participant you will receive two links, one for streaming the recorded presentations and one for the live Webex Panel Discussion in which your submitted questions will be answered.

- The first link is valid from Monday, 14 June, until Wednesday, 16 June. During these days, you can log in at any time and stream the lectures.
- The second link is for the Panelist Discussion and is valid on Thursday, 17 June, from 14.30 - 16.30 h. You can log in 30 minutes before the start.

Questions to be answered at the live Q&A Session should be send to atmp@gmp-compliance.org.
General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
   - Cancellation until 2 weeks prior to the conference 10%,
   - Cancellation until 1 weeks prior to the conference 50%,
   - Cancellation within 1 week prior to the conference 100%.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for any airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will be confirmed). (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

If the bill-to-address deviates from the specifications on the right, please fill out here: [Blank Lines]

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34
D-69007 Heidelberg
GERMANY